Millennium Management’s Vivos Therapeutics VVOS Stock Holding History

Millennium Management’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,001	Closed	-$31.3K	–	6511
2024 Q3	$31.3K	Buy	+12,001	New	+$31.4K	﹤0.01%	5747
2023 Q2	–	Sell	-765	Closed	-$7K	–	6738
2023 Q1	$7K	Buy	+765	New	+$16.7K	﹤0.01%	6085
2022 Q2	–	Sell	-450	Closed	-$30K	–	7557
2022 Q1	$30K	Buy	+450	New	+$29.4K	﹤0.01%	6549
2021 Q3	–	Sell	-527	Closed	-$65K	–	7301
2021 Q2	$65K	Sell	527 -2,629	-83%	-$428K	﹤0.01%	6338
2021 Q1	$524K	Sell	3,156 -181	-5%	-$32.3K	﹤0.01%	4790
2020 Q4	$493K	Buy	+3,337	New	+$609K	﹤0.01%	4204

Other funds holding VVOS

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's VVOS Position: Q4 2024 in Review

Millennium Management sold out of Vivos Therapeutics (VVOS) in Q4 2024, closing a stake of 12,001 shares — an estimated $31.3K sold.

Millennium Management first reported a position in VVOS in Q4 2020 and held it in 6 quarters. The position peaked at $524K in Q1 2021. 20 funds tracked by Wall St. Rank hold VVOS as of Q4 2024.

Millennium Management reported no remaining Vivos Therapeutics position as of Q4 2024 after selling out during the quarter.
Millennium Management sold 12,001 Vivos Therapeutics shares in Q4 2024, an estimated $31.3K.
Millennium Management first reported a position in Vivos Therapeutics in Q4 2020 and held it in 6 quarters.
Millennium Management's Vivos Therapeutics position peaked at $524K in Q1 2021.
20 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.